NO20062876L - Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater - Google Patents

Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater

Info

Publication number
NO20062876L
NO20062876L NO20062876A NO20062876A NO20062876L NO 20062876 L NO20062876 L NO 20062876L NO 20062876 A NO20062876 A NO 20062876A NO 20062876 A NO20062876 A NO 20062876A NO 20062876 L NO20062876 L NO 20062876L
Authority
NO
Norway
Prior art keywords
chemotherapy
compositions
methods
combined radio
relates
Prior art date
Application number
NO20062876A
Other languages
English (en)
Inventor
Graham Edmund Kelly
David Brown
Original Assignee
Novogen Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003906386A external-priority patent/AU2003906386A0/en
Application filed by Novogen Res Pty Ltd filed Critical Novogen Res Pty Ltd
Publication of NO20062876L publication Critical patent/NO20062876L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår kombinerte terapier som innbefatter radioterapi og kjemoterapi. Spesielt angår oppfinnelsen bruken av isoflavanoner og deres analoger i kombinasjon med radioterapi eller kjemoterapi i behandlingen av cancer og beslektede sykdommer og tilstander. Oppfinnelsen angår også sammensetninger og midler som kan brukes for samme og fremgangsmåter for deres fremstilling.
NO20062876A 2003-11-19 2006-06-19 Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater NO20062876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003906386A AU2003906386A0 (en) 2003-11-19 Combinational radiotherapy and chemotherapy compositions and methods
PCT/AU2004/001619 WO2005049008A1 (en) 2003-11-19 2004-11-19 Combinational radiotherapy and chemotherapy compositions and methods

Publications (1)

Publication Number Publication Date
NO20062876L true NO20062876L (no) 2006-08-08

Family

ID=34596421

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062876A NO20062876L (no) 2003-11-19 2006-06-19 Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater

Country Status (10)

Country Link
US (1) US20060167037A1 (no)
EP (1) EP1686981A4 (no)
JP (1) JP2007525485A (no)
CN (1) CN101123958A (no)
CA (1) CA2542351A1 (no)
IL (1) IL174741A0 (no)
MX (1) MXPA06005697A (no)
NO (1) NO20062876L (no)
NZ (1) NZ546150A (no)
WO (1) WO2005049008A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005201855B2 (en) * 2004-09-21 2012-03-29 Marshall Edwards, Inc. Chroman derived compounds and formulations thereof for use in therapy
JP4913056B2 (ja) * 2004-09-21 2012-04-11 マーシャル エドワーズ，インコーポレーテッド 置換クロマン誘導体、医薬品、および治療における使用
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
AU2005287865B2 (en) 2004-09-21 2012-02-16 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
EP2436680B1 (en) * 2004-09-21 2016-05-18 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
ES2360130T3 (es) * 2005-03-24 2011-06-01 Novogen Research Pty. Ltd. Dímeros de isoflavonoides.
WO2008113100A1 (en) * 2007-03-16 2008-09-25 Novogen Research Pty Ltd Method for inducing autophagy
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
TWI472525B (zh) 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
EP2635273B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
CN103183598B (zh) * 2011-12-28 2015-12-09 沈阳药科大学 1,2-二取代芳基-2-丙烯-1-酮类化合物及其用途
CN103349661B (zh) * 2013-07-12 2015-01-07 浙江省中医院 一种刺氟合剂的制备方法及应用
CA2936012C (en) * 2014-02-07 2023-03-07 Novogen Limited Functionalised benzopyran compounds and use thereof
WO2016073897A1 (en) 2014-11-06 2016-05-12 Northwestern University Inhibition of cancer cell motility
US10980774B2 (en) 2015-02-02 2021-04-20 Mei Pharma, Inc. Combination therapies
US9718799B2 (en) * 2015-05-11 2017-08-01 University Of Kentucky Research Foundation 3-aryl-4H-chromene-4-ones as antineoplastic agents for the treatment of cancer
US20190160004A1 (en) 2016-04-06 2019-05-30 Noxopharm Limited Improvements in cancer treatment
WO2017173498A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
JP2019513826A (ja) * 2016-04-06 2019-05-30 ノクソファーム リミティド 放射線療法の改善
US20190117620A1 (en) * 2016-04-22 2019-04-25 Noxopharm Limited Chemotherapy improvements
KR102005237B1 (ko) * 2017-02-28 2019-07-30 서울대학교산학협력단 에쿠올 유도체를 생산하는 재조합 대장균 및 이를 이용한 에쿠올 유도체 합성 방법
BR112020021194A2 (pt) 2018-04-18 2021-03-23 Constallation Pharmaceuticals, Inc. moduladores de enzimas modificadoras de metila, composições e usos dos mesmos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
CN114072140A (zh) * 2019-07-17 2022-02-18 讷克斯药物有限公司 使用异黄酮类化合物的免疫肿瘤治疗
ES2997972T3 (en) 2019-07-24 2025-02-18 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN113209076A (zh) * 2021-04-25 2021-08-06 上海市第六人民医院 大豆苷元在制备减轻铂类药物毒性的药物中的应用
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0617304B2 (ja) * 1982-09-09 1994-03-09 理化学研究所 制癌剤
JPS60178815A (ja) * 1984-02-24 1985-09-12 Rikagaku Kenkyusho 制癌剤
US5005588A (en) * 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
JP2514500B2 (ja) * 1991-09-14 1996-07-10 呉羽化学工業株式会社 多剤耐性抑制剤及び発現阻害剤
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US6004558A (en) * 1998-02-25 1999-12-21 Novogen, Inc. Methods for treating cancer with legume plant extracts
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
JP2001114687A (ja) * 1999-10-13 2001-04-24 Mitsui Norin Co Ltd 抗癌剤
AU2001271296A1 (en) * 2000-06-14 2001-12-24 Alla Shapiro Radioprotective agents
AU7131001A (en) * 2000-08-08 2001-12-24 Us Health Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury
WO2003039537A1 (en) * 2001-11-05 2003-05-15 Alla Shapiro Chemoprotectant compositions
EP1503751A4 (en) * 2002-04-09 2007-08-01 Novogen Res Pty Ltd THERAPEUTIC PROCESSES AND COMPOSITIONS WITH ISOFLAV-3-EN AND ISOFLAVAN STRUCTURES
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes

Also Published As

Publication number Publication date
NZ546150A (en) 2010-04-30
CN101123958A (zh) 2008-02-13
WO2005049008A1 (en) 2005-06-02
US20060167037A1 (en) 2006-07-27
CA2542351A1 (en) 2005-06-02
IL174741A0 (en) 2008-04-13
JP2007525485A (ja) 2007-09-06
EP1686981A1 (en) 2006-08-09
MXPA06005697A (es) 2006-08-17
EP1686981A4 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20064584L (no) Tetrahydropyridoindolderivater
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
NO20070782L (no) Tetrapeptidanaloger.
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
IL258880A (en) Diarylhydantoin compounds
NO20074446L (no) DR5-antistoffer og anvendelser derav
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20071078L (no) Antivirale forbindelser
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
TW200801008A (en) Protein kinase inhibitors
SG164368A1 (en) Treatment of cancer
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
NO20092637L (no) Fremgangsmater for behandling
NO20085422L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application